Such targeted combination chemotherapy may improve the treatment efficacy of both ALL and AML via two approaches: 1) ALL patients could be tested for Smad4-binding to exon12 of FPGS at diagnosis and/or upon relapse, thereby allowing clinicians to personalize the treatment protocol for individual ALL patients. This evidence concerns the gene SMAD4 and acute lymphoblastic leukemia.